The role of hyperthermia in regional alkylating agent chemotherapy

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5919-5929

  Abdel Wahab, Omar I ^a   Grubbs, Elizabeth ^a   Viglianti, Benjamin L ^b   Cheng, Tsung Yen ^a   Ueno, Tomio ^a   Ko, SaeHee ^a   Rabbani, Zahid ^a   Curtis, Simon ^a   Pruitt, Scott K ^a   Dewhirst, Mark W ^a,b   Tyler, Doug S ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Duke University   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; MELPHALAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG TUMOR LEVEL; FEMALE; FIBROSARCOMA; HEAT TREATMENT; HYPERTHERMIA; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COMBINED MODALITY THERAPY; EXTREMITIES; FEMALE; FIBROSARCOMA; HYPERTHERMIA, INDUCED; MELPHALAN; RATS; RATS, WISTAR; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 4444378467     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0096     Document Type: Article

References (45)

1. Creech O, Krementz E, Ryan R, Winbald J. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958; 148:616.
2. Hohenberger P, Kettelhack C. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma. Oncology 1998;55(2):89-102.
3. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol 1988; 14(2):101-10.
4. van de Merwe SA, van den Berg AP, Kroon BB, van den Berge AW, Klaase JM, van der Zee J. Modification of human tumour and normal tissue pH during hyperthermic and normothermic antiblastic regional isolation perfusion for malignant melanoma: a pilot study. Int J Hyperthermia 1993;9(2):205-17.
5. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001;44(3):189-92.
6. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9(2):127-36.
7. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14(3):238-47.
8. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer (Phila.) 1967;20(9):1351-81.
9. Woodhall B, Pickrill KL, Georgiade NG, Mahaley MS, Dukes HT. Effect of hyperthermia upon cancer chemotherapy-application to external cancer of head and face structures. Ann Surg 1960;151:750-9.
10. Crile G. Heat as an adjunct to the treatment of cancer: experimental studies. Cleve Clin Quart 1961;28:75-89.
11. Shingleton WW, Bryan FA, O'Quinn WL, Krueger LC. Selective heating and cooling of tissue in cancer chemotherapy. Ann Surg 1962; 156:408-16.
12. Klaase JM, Kroon BB, Eggermont AM, et al. A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer 1995;31A(1):58-63.
13. Di Filippo F, Anza M, Rossi CR, et al. The application of hyperthermia in regional chemotherapy. Semin Surg Oncol, 1998;14(3): 215-23.
14. Kelley ST, Menon C, Buerk DG, Bauer TW, Fraker DL. Acidosis plus melphalan induces nitric oxide-mediated tumor regression in an isolated limb perfusion human melanoma xenograft model. Surgery (St. Louis) 2002;132(2):252-8.
15. Grubbs E, Friedman H, Colvin M, et al. In-transit melanoma: The role of alkylating agent resistance in regional therapy. J Am Coll Surg. In press 2004.
16. Hahn G. Hyperthermia and cancer. New York: Plenum Press; 1982.
17. Clark J, Grabs AJ, Parsons PG, Smithers BM, Addison RS, Roberts MS. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994;4(6):365-70.
18. Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro. Int J Hyperthermia 2002;18(4):307-15.
19. Hettinga JV, Lemstra W, Meijer C, et al. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 1997;75(12):1735-43.
20. Toyota N, Strebel FR, Stephens LC, et al. Therapeutic efficacy and apoptosis and necrosis kinetics of doxorubicin compared with cisplatin, combined with whole-body hyperthermia in a rat mammary adenocarcinoma. Int J Cancer 1998;76(4):499-505.
21. Takemoto M, Kuroda M, Urano M, et al. The effect of various chemotherapeutic agents given with mild hyperthermia on different types of tumours. Int J Hyperthermia 2003;19(2):193-203.
22. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999;15(2):79-107.
23. Song CW. Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 1984;44(10 Suppl):4721s-30s.
24. Sakaguchi Y, Stephens LC, Makino M, et al. Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Res 1995;55(22):5459-64.
25. Wondergem J, Bulger RE, Strebel FR, et al. Effect of cis- diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Res 1988;48(2):440-6.
26. van der Zee J, Kroon BB, Nieweg OE, van de Merwe SA, Kampinga HH. Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer 1997; 33(10):1546-50.
27. Dewhirst MW, Viglianti BL, Lora-Michiels M, Hanson M, Hoopes PJ. Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia. Int J Hyperthermia 2003;19(3): 267-94.
28. Thrall DE, Rosner GL, Azuma C, et al. Using units of CEM 43°C T90, local hyperthermia thermal dose can be delivered as prescribed. Int J Hyperthermia 2000;16(5):415-28.
29. Adair CG, Burns DT, Crockard AD, Desai ZR, Harriott M. Modified extraction and chromatography for the measurement of plasma melphalan by ion-pair high-performance liquid chromatography. J Chromatogr 1984;336(2):429-33.
30. Huuhtanen RL, Blomqvist CP, Wiklund TA, et al. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer 1999;79(5-6):945-51.
31. Elias JM. Cell proliferation indexes: a biomarker in solid tumors. Biotech Histochem 1997;72(2):78-85.
32. Gu Y, Jow GM, Moulton BC, et al. Apoptosis in decidual tissue regression and reorganization. Endocrinology 1994;135(3):1272-9.
33. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119(3):493-501.
34. Oleson JR, Samulski TV, Leopold KA, et al. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys 1993;25(2):289-97.
35. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138(4):867-73.
36. Plaat BE, Molenaar WM, Mastik MF, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res 1999;5(7):1650-7.
37. Honess DJ, Donaldson J, Workman P, Bleehen NM. The effect of systemic hyperthermia on melphalan pharmacokinetics in mice. Br J Cancer 1985;51(1):77-84.
38. Laskowitz DT, Elion GB, Dewhirst MW, et al. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. Radiat Res 1992;129(2): 218-23.
39. Fernandes RS, Cotter TG. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. Biochem Pharmacol 1994; 48(4):675-81.
40. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002;43:33-56.
41. Harmon BV, Takano YS, Winterford CM, Gobe GC. The role of apoptosis in the response of cells and tumours to mild hyperthermia. Int J Radiat Biol 1991;59(2):489-501.
42. Sekiguchi I, Suzuki M, Tamada T, Shinomiya N, Tsuru S, Murata M. Effects of cisplatin on cell cycle kinetics, morphological change, and cleavage pattern of DNA in two human ovarian carcinoma cell lines. Oncology 1996;53(1):19-26.
43. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108(2):153-64.
44. Ohnishi K, Ohnishi T. Heat-induced p53-dependent signal transduction and its role in hyperthermic cancer therapy. Int J Hyperthermia 2001;17(5):415-27.
45. Stephens LC, Hunter NR, Ang KK, Milas L, Meyn RE. Development of apoptosis in irradiated murine tumors as a function of time and dose. Radiat Res 1993;135(1):75-80.